Advertisement

Topics

Report: Biosimilars to Put Pressure on Breast Cancer Drug Market

07:00 EDT 2 Aug 2017 | PharmPro

Global HER2-positive breast cancer market to face challenges from biosimilars through to 2025, says GlobalData. EU and Japan patents protecting Herceptin expired in 2014, while the drug’s patent in the U.S. will expire in 2019.
Contributed Author: 
GlobalData
Topics: 

Original Article: Report: Biosimilars to Put Pressure on Breast Cancer Drug Market

NEXT ARTICLE

More From BioPortfolio on "Report: Biosimilars to Put Pressure on Breast Cancer Drug Market"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...